Alkermes ALKS Stock
Alkermes Price Chart
Alkermes ALKS Financial and Trading Overview
| Alkermes stock price | 30.7 USD |
| Previous Close | 26.55 USD |
| Open | 26.55 USD |
| Bid | 26.55 USD x 400 |
| Ask | 26.63 USD x 400 |
| Day's Range | 26.08 - 26.72 USD |
| 52 Week Range | 25.56 - 36.45 USD |
| Volume | 1.04M USD |
| Avg. Volume | 1.79M USD |
| Market Cap | 4.39B USD |
| Beta (5Y Monthly) | 0.425 |
| PE Ratio (TTM) | 12.847826 |
| EPS (TTM) | 2.01 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 41.5 USD |
ALKS Valuation Measures
| Enterprise Value | 3.45B USD |
| Trailing P/E | 12.847826 |
| Forward P/E | 13.231343 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 2.9165356 |
| Price/Book (mrq) | 2.70192 |
| Enterprise Value/Revenue | 2.29 |
| Enterprise Value/EBITDA | 8.548 |
Trading Information
Alkermes Stock Price History
| Beta (5Y Monthly) | 0.425 |
| 52-Week Change | 2.03% |
| S&P500 52-Week Change | 18.63% |
| 52 Week High | 36.45 USD |
| 52 Week Low | 25.56 USD |
| 50-Day Moving Average | 28.99 USD |
| 200-Day Moving Average | 30.16 USD |
ALKS Share Statistics
| Avg. Volume (3 month) | 1.79M USD |
| Avg. Daily Volume (10-Days) | 2.15M USD |
| Shares Outstanding | 165.08M |
| Float | 162.42M |
| Short Ratio | 6.66 |
| % Held by Insiders | 1.48% |
| % Held by Institutions | 106.74% |
| Shares Short | 12.57M |
| Short % of Float | 11.03% |
| Short % of Shares Outstanding | 7.61% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 2:1 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2024 |
| Most Recent Quarter (mrq) | June 30, 2025 |
| Next Fiscal Year End | December 31, 2025 |
Profitability
| Profit Margin | 23.14% |
| Operating Margin (ttm) | 23.79% |
| Gross Margin | 85.12% |
| EBITDA Margin | 26.79% |
Management Effectiveness
| Return on Assets (ttm) | 10.48% |
| Return on Equity (ttm) | 23.93% |
Income Statement
| Revenue (ttm) | 1.51B USD |
| Revenue Per Share (ttm) | 9.21 USD |
| Quarterly Revenue Growth (yoy) | -2.10% |
| Gross Profit (ttm) | 1.28B USD |
| EBITDA | 403.27M USD |
| Net Income Avi to Common (ttm) | 348.09M USD |
| Diluted EPS (ttm) | 2.07 |
| Quarterly Earnings Growth (yoy) | -4.70% |
Balance Sheet
| Total Cash (mrq) | 1.02B USD |
| Total Cash Per Share (mrq) | 6.15 USD |
| Total Debt (mrq) | 72.68M USD |
| Total Debt/Equity (mrq) | 4.47 USD |
| Current Ratio (mrq) | 3.232 |
| Book Value Per Share (mrq) | 9.843 |
Cash Flow Statement
| Operating Cash Flow (ttm) | 521M USD |
| Levered Free Cash Flow (ttm) | 345.67M USD |
Profile of Alkermes
| Country | United States |
| State | N/A |
| City | Dublin |
| Address | Connaught House |
| ZIP | D04 C5Y6 |
| Phone | 353 1 772 8000 |
| Website | https://www.alkermes.com |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector(s) | Healthcare |
| Full Time Employees | 1800 |
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
Q&A For Alkermes Stock
What is a current ALKS stock price?
Alkermes ALKS stock price today per share is 30.7 USD.
How to purchase Alkermes stock?
You can buy ALKS shares on the Tech Market Large exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Alkermes?
The stock symbol or ticker of Alkermes is ALKS.
Which industry does the Alkermes company belong to?
The Alkermes industry is Drug Manufacturers - Specialty & Generic.
How many shares does Alkermes have in circulation?
The max supply of Alkermes shares is 165.12M.
What is Alkermes Price to Earnings Ratio (PE Ratio)?
Alkermes PE Ratio is 15.27363200 now.
What was Alkermes earnings per share over the trailing 12 months (TTM)?
Alkermes EPS is 2.01 USD over the trailing 12 months.
Which sector does the Alkermes company belong to?
The Alkermes sector is Healthcare.
Alkermes ALKS included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| US Tech Composite IXIC | 23724.96 USD — |
+0.61
|
9.88B USD — | 23628.82 USD — | 23946.23 USD — | — - | 9.88B USD — |
| Dow Jones U.S. Biotechnology In DJUSBT | 3015.8 USD — |
+0.19
|
129.64M USD — | 2963.67 USD — | 3024.24 USD — | — - | 129.64M USD — |
| US Tech Biotechnology Total Retu XNBI | 5830.62 USD — |
+1.2
|
— — | 5732.51 USD — | 5837.42 USD — | — - | — — |
| US Tech US Smart Pharmaceuticals NQSSPH | 1603.8 USD — |
+0.75
|
— — | 1582.27 USD — | 1607.03 USD — | — - | — — |
| US Tech AlphaDEX Multi Cap Growt NQDXUSMLTCG | 3514.71 USD — |
+0.87
|
— — | 3485.13 USD — | 3527.41 USD — | — - | — — |
| US Tech Biotechnology NBI | 5366.46 USD — |
+1.2
|
— — | 5276.16 USD — | 5372.71 USD — | — - | — — |
| US Tech Health Care IXHC | 1115.96 USD — |
+0.87
|
— — | 1099.74 USD — | 1117.62 USD — | — - | — — |
| US Tech Composite Total Return XCMP | 29137.78 USD — |
+0.62
|
— — | 29019.72 USD — | 29409.52 USD — | — - | — — |
| US Tech Global Select Market Com NQGS | 11620.1 USD — |
+0.59
|
— — | 11575.56 USD — | 11733.88 USD — | — - | — — |
| Stlmt ID US Tech Biotechnology NBX | 3995.9 USD — |
-4.37
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
| ^DRG DRG | 999.47 USD — |
+0.07
|
— — | 986.34 USD — | 1001.83 USD — | — - | — — |
- {{ link.label }} {{link}}